Precision Biologics’ New Antibody Targets Tumor Activity in Ovarian, Other Cancer Cells

Precision Biologics’ New Antibody Targets Tumor Activity in Ovarian, Other Cancer Cells
Dallas-based Precision Biologics says its new antibody targets tumor cells expressing the NEO-201 neo-antigen, which are present in ovarian and gastrointestinal cancers. The company presented new preclinical data earlier this month at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, D.C. The findings revealed that the new monoclonal antibody can induce potent immune responses against NEO-201-positive

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *